Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
Regulatory agencies request an assessment of cardiovascular safety for all “new” oral anti-diabetic drugs in order to avoid possible negative effects on cardiovascular events. Dipeptidyl peptidase 4 inhibitors...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Cristiana Vitale, Giuseppe M. C. Rosano and Krishna Prasad Source Type: research